A Clearinghouse for Information about Blood Clots (DVT/)PE) and Clotting Disorders (thrombophilia) provided as a public service by the University of North Carolina Blood Research Center

Author: Clot Connect

  • Warfarin Interruption for Surgery: Bridging with LMWH Often Not Needed

    Stephan Moll, MD writes:  Interesting and relevant publication today in the New England Journal of Medicine (NEJM)

  • Reversal Agent for Pradaxa: Important NEJM Publication Today

    Stephan Moll, MD writes… A publication in the New England Journal of Medicine today reports on the use of the Pradaxa® (Dabigatran) antidote Idarucizumab in patients on Pradaxa® who present with major bleeding or require urgent surgery [ref 1]. 

  • Thrombophilia – Information Handout for Patients

    Stephan Moll, MD writes… An information article on various aspects of thrombophilia, written for patients and family members, was published today – available here – as a Vascular Disease Patient Information Page in the journal Vascular Medicine.  It addresses (a) in which patient with venous thromboembolism to consider thrombophilia  testing, (b) what tests might be appropriate to do, (c) how the test results…

  • ASH 2014 Highlights: Thrombosis and Anticoagulation

    Stephan Moll, MD writes… The annual American Society of Hematology (ASH) meeting took place in Dec 2014 in San Francisco.  A summary of the clinically relevant thrombosis and anticoagulation presentation and abstracts is presented here (Top 10 ASH Highlights).   Disclosure: I have been a consultant to Portola, Daiichi, Janssen, and Boehringer-Ingelheim.  Last updated: Jan…

  • Fourth NOAC FDA Approved for DVT, PE and Atrial Fibrillation: Savaysa (Edoxaban)

    Stephan Moll, MD writes…. Today (Jan 8th, 2015) the FDA approved yet another new oral anticoagulant, Savaysa (edoxaban), for the treatment of DVT and PE, as well as for atrial fibrillation. The FDA press release  is here (link).  Savaysa is the 4th of the NOACS now approved for VTE treatment. This table summarizes the differences, advantages and disadvantages comparing the 4 drugs. The…

  • Two Things Physicians Should Avoid

    Stephan Moll, MD writes (Dec 17, 2014)…  The American Society of Hematology (ASH) published last week as part of its Choosing Wisely® campaign two things that physicians dealing with DVT, PE and anticoagulants should avoid [ref 1].

  • Fascinating New “Anticoagulant”: It Protects from VTE, but Does Not Increase Bleeding

    Stephan Moll, MD writes (on Dec 8th, 2014)… A publication this week in the New England Journal of Medicine reports on an investigational drug that protects patients from VTE without increasing the risk of bleeding [reference below]. Too good to be true? Possibly, but may be not. Additional studies will have to tell.

  • VTE Prophylaxis in Hospitalized Patients: Guidance Document

    Stephan Moll, MD writes (on 12/5/2014)… Venous thromboembolism (VTE) prophylaxis in hospitalized patients is important; it is also mandated by the Joint Commission [ref].  We have developed at the University of North Carolina (UNC) a guidance document (link here; UNC VTE prophylaxis guidance document) as a resource for our health care professionals to assist in…